Giles, Francis J.

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Fischer, T., Stone, R. M., DeAngelo, D. J., Galinsky, I., Estey, E., Lanza, C., Fox, E., Ehninger, G., Feldman, E. J., Schiller, G. J., et al. (2010) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 504

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 421

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Schimmer, A. D., O'Brien, S., Kantarjian, H., Brandwein, J., Cheson, B. D., Minden, M. D., Yee, K., Ravandi, F., Giles, F., Schuh, A., et al. (2008) · Clinical Cancer Research

Acute Myeloid Leukemia ResearchCell death mechanisms and regulation

Cited by 192

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Konduri, K., Gallant, J.-N., Chae, Y. K., Giles, F. J., Gitlitz, B. J., Gowen, K., Ichihara, E., Owonikoko, T. K., Peddareddigari, V., Ramalingam, S. S., et al. (2016) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 144

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 123

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017) · Cancer Immunology, Immunotherapy

Cancer Immunotherapy and BiomarkersDiabetes and associated disorders

Cited by 121

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA

Chae, Y. K., Davis, A. A., Carneiro, B. A., Chandra, S., Mohindra, N., Kalyan, A., Kaplan, J., Matsangou, M., Pai, S., Costa, R., et al. (2016) · Oncotarget

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 110

Molecular Remissions Induced by Liposomal-Encapsulated All-Trans Retinoic Acid in Newly Diagnosed Acute Promyelocytic Leukemia

Estey, E. H., Giles, F. J., Kantarjian, H., O’Brien, S., Cortes, J., Freireich, E. J., Lopez-Berestein, G., & Keating, M. (1999) · Blood

Retinoids in leukemia and cellular processesAcute Myeloid Leukemia Research

Cited by 105

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

Radich, J. P., Hochhaus, A., Masszi, T., Hellmann, A., Stentoft, J., Casares, M. T. G., García-Gutiérrez, J. V., Conneally, E., le Coutre, P. D., Gattermann, N., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 91

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Mita, M., Kelly, K. R., Mita, A., Ricart, A. D., Romero, O., Tolcher, A., Hook, L., Okereke, C., Krivelevich, I., Rossignol, D. P., et al. (2011) · Clinical Cancer Research

Angiogenesis and VEGF in CancerCell Adhesion Molecules Research

Cited by 71

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J. (2017) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 70

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Borden, B. A., Baca, Y., Xiu, J., Tavora, F., Winer, I., Weinberg, B. A., Vanderwalde, A. M., Darabi, S., Korn, W. M., Mazar, A. P., et al. (2021) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Cited by 15